Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
US Department of Justice
QuintilesIMS
Accenture
Cantor Fitzgerald
McKesson
Fish and Richardson
Teva
Julphar

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,877,933

« Back to Dashboard

Which drugs does patent 8,877,933 protect, and when does it expire?

Patent 8,877,933 protects NEXAVAR and is included in one NDA.

This patent has thirty-seven patent family members in thirty-one countries.
Summary for Patent: 8,877,933
Title:Thermodynamically stable form of a tosylate salt
Abstract: The present invention relates to a novel form, thermodynamically stable at room temperature, of the tosylate salt of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}- -N-methylpyridine-2-carboxamide, to processes for its preparation, to medicaments comprising it and to its use in the control of disorders.
Inventor(s): Grunenberg; Alfons (Dormagen, DE), Lenz; Jana (Wuppertal, DE)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:11/664,363
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,877,933
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Process;

Drugs Protected by US Patent 8,877,933

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA. ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,877,933

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04023130Sep 29, 2004
PCT Information
PCT FiledSeptember 20, 2005PCT Application Number:PCT/EP2005/010119
PCT Publication Date:April 06, 2006PCT Publication Number: WO2006/034797

International Family Members for US Patent 8,877,933

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea 20090018224 ➤ Try a Free Trial
South Korea 20070058537 ➤ Try a Free Trial
South Korea 101381454 ➤ Try a Free Trial
South Korea 20130004385 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
UBS
US Army
Julphar
Fuji
Cipla
Accenture
Deloitte
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.